ACS Medicinal Chemistry Letters

UNIVERSITY^{OF} BIRMINGHAM

Subscriber access provided by University of Birmingham

Fluorescent H Receptor Squaramide-Type Antagonists: Synthesis, Characterization and Applications

Sabrina Biselli, Inês Alencastre, Katharina Tropmann, Daniela Erdmann, Mengya Chen, Timo Littmann, André F. Maia, Maria Gomez-Lazaro, Miho Tanaka, Takeaki Ozawa, Max Keller, Meriem Lamghari, Armin Buschauer, and Günther Bernhardt

ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.0c00033 • Publication Date (Web): 20 Jul 2020 Downloaded from pubs.acs.org on July 24, 2020

Just Accepted

Letter

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

7

8 9

15

16

17

18

19 20

21

22

23

24

25

26

27

28 29

30 31 32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58 59

60

Fluorescent H₂ Receptor Squaramide-Type Antagonists: Synthesis, Characterization and Applications

Sabrina Biselli,^{*,‡,•} Inês Alencastre,^{§,•} Katharina Tropmann,[‡] Daniela Erdmann,^{‡,‡} Mengya Chen,^{‡,†} Timo Littmann,^{‡,‡} André F. Maia,^{§,•} Maria Gomez-Lazaro,^{§,•} Miho Tanaka,[†] Takeaki Ozawa,[†] Max Keller,[‡] Meriem Lamghari,^{§,•} Armin Buschauer^{‡,} and Günther Bernhardt^{*,‡}

[‡] Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstrasse 31, D-93053 Regensburg, Germany

[§] i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal

* INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal

° IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal

[†] Department of Chemistry, School of Science, University of Tokyo, 7-3-1 Bunkyo-ku, Hongo, Tokyo 113-0033, Japan

ABSTRACT: Fluorescence labeled ligands have been gaining importance as molecular tools, enabling receptor-ligand-binding studies by various fluorescence-based techniques. Aiming at red-emitting fluorescent ligands for the hH₂R, a series of squaramides labeled with pyridinium or cyanine fluorophores (**19-27**), was synthesized and characterized. The highest hH₂R affinities in radioligand competition binding assays were obtained in the case of pyridinium labeled antagonists **19-21** (pK_i: 7.71-7.76) and cyanine labeled antagonists **23** and **25** (pK_i: 7.67, 7.11). These fluorescent ligands proved to be useful tools for binding studies (saturation and competition binding as well as kinetic experiments), using confocal microscopy, flow cytometry and high content imaging. Saturation binding experiments revealed pK_d values comparable to the pK_i values. The fluorescent probes **21**, **23** and **25** could be used to localize H₂ receptors in HEK cells and to determine the binding affinities of unlabeled compounds.

KEYWORDS: histamine H₂ receptor, squaramides, fluorescence labeling, flow cytometry, high content imaging, confocal microscopy

The histamine H_2 receptor (H_2R), an aminergic GPCR, is one of the histamine receptor subtypes ($H_{1-4}R$) which mediate the action of the biogenic amine histamine (1). Activation of H_2R results e.g. in gastric acid secretion,^{1,2} and positive inotropic and chronotropic effects³. In humans, the H_2R is located on parietal cells in the stomach,² in the brain,^{4,5} on neutrophils and eosinophils⁶ as well as on smooth muscle cells⁷. However, the (patho)-physiological role of the H_2R , especially in the brain, is still far from being understood.

During the past few decades, fluorescence labeled GPCR ligands have gained increasing importance as molecular tools for the investigation of ligand-receptor-interactions as they represent a complement or even an attractive alternative to radioligands with respect to waste disposal, safety protocols and costs.⁸⁻¹¹ Various fluorescent ligands for aminergic GPCRs have been reported, for example for muscarinic¹²⁻¹⁴. adrenergic^{15,16}, histamine $H_1^{17,18}$ and H_3^{19-21} receptors. There are different fluorophore core structures available for labeling²², e.g. BODIPY, rhodamine, dansyl/NBD or cyanine.⁸ Most of the fluorescent ligands reported for the H_2R are emitting at wavelengths below 550 nm.^{23,24} The majority of reportconsist fluorescent H₂R ligands ed of а piperidinomethylphenoxypropylamino pharmacophore, derived either from roxatidine (2), iodoaminopotentidine (3) or BMY 2536 (4), which were linked to the fluorophore by an alkyl chain (Figure 1). Labeling with relatively small chromophores such as the N-methylanthranilic acid amide or

NBD-analogs resulted in fluorescent ligands with high affinity for the H₂R (5, 6: pA₂ or pK_i > 7.0) (Figure 1).^{23,24} However, 5 and 6 were inapplicable for cell-based methods e.g. flow cytometry due to the high cellular autofluorescence at the emission wavelength, giving low signal-to-noise ratios.^{23,24} In order to expand the range of applications, well characterized fluorescent H₂R ligands labeled with red-emitting fluorophores (emission wavelength >600 nm) are required. First attempts to the development of such ligands were already made by labeling piperidinomethylphenoxypropylamino pharmacophores with the cvanine dye S0436 (7^{25} and 8^{26} (Note to the paper authored by Petrache *et al.*²⁶, the ligands in that paper were prepared and pharmacologically characterized in our laboratories. The authors sketchily (compounds were "chemical synthesized"²⁶) published very preliminary data without our knowledge and consent in a case of severe scientific misconduct)), BODIPY 650/665 (9²⁵) or BODIPY 630/650 (10²⁷) (Figure 1). AB118175, an aminopotentidine derivative labeled with BODIPY 630/650 (chemical structure not disclosed, alleged structure of 10 was deducted by the provided molecular formula $(C_{48}H_{56}BF_2N_9O_4S)^{27}$, is the only commercially available fluorescent ligand for H₂R, but the exact chemical structure is elusive and the high costs compromise its appropriateness as a H₂R fluorescent ligand. Additionally, AB118175 and the other red-emitting H₂R fluorescent ligands lack a comprehensive pharmacological characterization (only functional data available, no subtype selectivity) and the suitability for binding studies by fluorescence-based techniques (e.g. confocal microscopy, flow cytometry) was only partially reported.²⁵⁻²⁷ Furthermore, ligands **8** and **9** were reported to have only moderate H₂R activities (pK_b : 6.89²⁶ and 6.59²⁵).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21 22

23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

38

39

40

41 42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58 59

60

Here, we describe the synthesis and characterization of high affinity fluorescent H_2R antagonists with improved optical and physicochemical properties to gain access to a wide range of potential applications, in particular to confocal microscopy and to high throughput/content imaging.

Replacing the propionic acid amide of the high affinity radioligand [³H]UR-DE257 (11) (K_d value: 31 nM)²⁸, a squaramide derived from BMY 2536 (4)²⁹, by red-emitting fluorophores was the starting point for the development of high affinity fluorescent hH₂R ligands. As the physicochemical properties of the fluorescent labels can considerably effect e.g. non-specific binding or internalization,³⁰ we chose two different types of red-emitting fluorophores with various electrical charge: the positively charged pyrilium dye (Py-5, 12) and differently charged cyanine dyes (positive: S0223 (13a), neutral: S0436 (14a) or negative: S0386 (15a), free acids) (Scheme 1).



Figure 1. Chemical structures of histamine (1), reported H_2R standard antagonists (2-4), fluorescent H_2R ligands (5-10) and the radioligand [³H]UR-DE257 (11).^{5,23-29}

The synthesis of the amine precursors **16-18** and BMY 2536 (**4**) according to previously published procedures,^{29,31} is described in the supporting information. The Py-5 labeled fluorescent ligands **19-21** were synthesized by direct coupling of Py-5 (**12**, chameleon label³²) with the respective amine precursor **16-18** under basic conditions (Scheme 1). The reaction progressed rapidly accompanied by an immediate change in color from blue to red. The cyanine labeled fluorescent ligands **22-27** were derived from the amine precursors **16-17** by amide coupling using succinimidyl esters of the respective fluorescent dves (**13b-15b**).

The fluorescence quantum yields of representative compounds (20, 21, 23, 25, 27) were determined in PBS at pH 7.4 and PBS containing 1% (w/v) of BSA (Table S1, Figure S61, Supporting Information). For all investigated compounds, fluorescence quantum yields, determined in PBS containing 1% BSA, were higher compared to the quantum yields determined in PBS devoid of protein. Fluorescence is strongly dependent on the environment of the fluorophore; this phenomenon can be explained by intermolecular hydrophobic and electrostatic interactions of the fluorescent ligand with proteins.³³ Additionally, ligands are flexible in solution and become more rigid upon binding, which generally leads to an increase in quantum yield.³³ Therefore, fluorescent ligands are not suitable for the determination of absolute values (e.g. number of specific binding sites B_{max}), but are valuable tools for the determination of dissociation constants (pK_d , and pK_i), which are accessible by measuring relative fluorescence intensities, by analogy with the determination of count rates (cpm/cps) in competition radioligand binding. The Py-5 labeled compounds 20 and 21 showed an excitation maximum at 481 nm and an emission maximum at 646 nm in the presence of BSA. The cyanine labeled compounds 23 and 25 showed an excitation maximum at 663-667 nm and an emission maximum at 672-676 nm in the presence of BSA. Therefore, the Py-5 labeled compounds 19-21 can be excited with an argon laser at 488 nm and the cyanine labeled compounds 22-27 by a red laser at 635 nm.

The fluorescent ligands 19-27, BMY2536 (4) and the amine precursors 16-18 were investigated in equilibrium competition binding experiments on membrane preparations from Sf9 insect cells expressing the hH_2R - $G_{s\alpha S}$ fusion protein, coexpressing hH₁R and RGS4, or co-expressing either the hH₃R or the hH₄R and $G_{\alpha i2}$ and $G_{\beta 1\gamma 2}$ proteins (Table 1; Table S2, Figures S62 and S63, Supporting Information).³⁴ Radioligand competition binding experiments revealed that most of the fluorescent labels were tolerated with no or only a slight decrease in affinity. Exceptions were the cyanine labeled ligands 26 and 27, in which the introduction of the S0387 fluorophore with a negative charge resulted in a decrease in hH₂R affinity $(pK_i: 26, 5.69; 27, 5.88)$ compared to the corresponding amine-precursors (pK_i : 16, 6.52; 17, 7.87). The Py-5 labeled ligands 19-21 showed, irrespective of linker length, high hH₂R affinities (pK_i : 7.71-7.76) in the same range as the parent compound BMY 25368 (4) (pK_i: 7.80). In case of 19, the hH_2R affinity even increased with labeling (pK_i of amine precursor 16: 6.52, pK_i of 19: 7.75). In the cyanine dye series, ligand 23, precursor 17 (n=6, Table 1) labeled with fluorophore S0223 (positive charge), and ligand 25, precursor 17 (n=6, Table 1) labeled with fluorophore S0436 (no charge), showed the highest hH_2R affinity (pK_i: 23, 7.67; 25, 7.11). Interestingly, labeling with Py-5, S0223 and S0436 led to an

Scheme 1. Chemical structures of Py-5 (12), the free acids S0223 (13a), S0436 (14a), S0387 (15a) and the succinimidyl esters S2197 (13b), S0S0536 (14b), S0586 (15b), as well as the synthesis of the fluorescent ligands 19-27.



Reagents and conditions: i) DMF, TEA or DIPEA, rt, 90-120 min, 24-32%; ii) DMF, DIPEA, rt, 45-90 min, 18-44%.

increase in hH₁R and hH₃R receptor affinity up to two orders of magnitude compared to the corresponding amine precursor (Table S2, Figure S62, Supporting Information). The pyridinium labeled ligands **19-21** and the cyanine labeled ligands **23** and **25** showed a slight preference for the hH₂R over the hH₁R and hH₃R. In case of the cyanine labeled ligand **24**, precursor **16** (n=4) labeled with fluorophore S0436 (no charge), the preference changed in favor of the hH₃R. Interestingly, cyanine ligand **22**, precursor **16** (n=4) labeled with fluorophore S0223 (positive charge), showed a high hH₁R affinity (pK_i of 7.88) with a 20-fold selectivity for the hH₁R over the hH₂R. The compounds **19-21**, **23** and **25**, which were investigated for hH₄R affinity, showed a 70 to 150-fold selectivity for the hH₂R over hH₄R (Table S2, Figure S63, Supporting Information).

The amine precursors **16-18**, BMY 25368 (4) and representative fluorescent ligands (20, 21, 23 and 25) were functionally characterized in a GTP γ S binding assay on membrane preparations of Sf9 insect cells expressing the hH₂R-G_{saS} fusion protein (Table 1; Figure S64, Supporting Information).³³ The investigated compounds proved antagonists with the calculated pK_b values being in a good agreement with the pK_i values from radioligand competition binding.

Furthermore, representative fluorescent ligands (**20**, **21**, **23** and **26**) were investigated for hH₂R agonism in a β -arrestin2 recruitment assay on HEK293T- β -Arr2-hH₂R cells (Figure S65, Supporting Information). None of the investigated ligands showed any β -arrestin2 recruitment, indicating that no β -arrestin2 mediated internalization of the receptor-ligand-complex took place.

The hH_2R binding of the fluorescent ligands **21**, **23** and **25** was also investigated by confocal microscopy (Figure 2). After 20 min of incubation, all investigated ligands were still localized at the cell membrane of HEK293T-hH₂R-qs5 cells.

Table 1. H₂R affinities and antagonistic activities as well as HR selectivity profiles.

compd.	n ^a	Fluorophore .	hH ₂ R					HR selectivity profile
			pK _i ^b	pK_d flow cytom. ^c	pK_d high content imaging ^d		$pK_b (pEC_{50})^e$	ratios of K_i
					automated cell imaging	imaging flow cytometry		${{ m H}_1 R} / {{ m H}_2 R} / {{ m H}_3 R} / \ {{ m H}_4 R^f}$
His (1)	-	-	6.53 ± 0.04	n.a.	n.a.	n.a.	(5.80 ± 0.06)	- / 1 / 0.5 / 0.1
4	-	-	7.80 ± 0.01^{g}	n.a.	n.a.	n.a.	7.03 ± 0.02	- / 1 / 1300 / -
16	4	-	6.52 ± 0.04	n.a.	n.a.	n.a.	5.76 ± 0.22	33 / 1 / 36 / 33
17	6	-	7.87 ± 0.02	n.a.	n.a.	n.a.	6.73 ± 0.08	740 / 1 / 620 / 740
18	7	-	7.86 ± 0.02	n.a.	n.a.	n.a.	7.06 ±0.13	380 / 1 / 550 / 720
19	4	Py-5	7.75 ± 0.02	7.55 ± 0.02	7.13 ± 0.01	7.06 ± 0.03	n.d.	6 / 1 / 20 / 70
20	6	Py-5	7.71 ± 0.04	7.84 ± 0.07	n.d.	n.d.	7.21 ± 0.04	5 / 1 / 4 / 120
21	7	Py-5	7.76 ± 0.01	7.73 ± 0.09	7.05 ± 0.04	7.19 ± 0.03	7.85 ± 0.10	4 / 1 / 6 / 160
22	4	S0223	6.57 ± 0.02	6.54 ± 0.05	6.92 ± 0.06	n.d.	n.d.	1 / 20 / 8 / 180
23	6	S0223	7.67 ± 0.07	7.89 ± 0.07	7.82 ± 0.10	n.d.	7.73 ± 0.04	2 / 1 / 3 / 50
24	4	S0436	6.49 ± 0.04	6.25 ± 0.21	6.77 ± 0.09	n.d.	n.d.	2/2/1/-
25	6	S0436	7.11 ± 0.01	7.32 ± 0.02	7.79 ± 0.13	n.d.	6.49 ± 0.03	6 / 1 / 3 / 130
26	4	S0387	5.69 ± 0.08	n.d.	n.d.	n.d.	n.d.	-/1/2/-
27	6	S0387	5.88 ± 0.09	n.d.	6.35 ± 0.04	n.d.	n.d.	n.d.

^{*a*}Length of the linker given as the number of carbon atoms. ^{*b*}Determined by radioligand competition binding with [³H]UR-DE257 (K_d = 12.2 nM, c= 20 nM) at membrane preparations of Sf9 insect cells expressing the hH₂R-G_{saS} fusion protein; mean values ± SEM from three independent experiments (each performed in triplicate). ^{*c*}Determined by flow cytometric saturation binding at HEK293T-hH₂R-qs5 cells; mean values ± SEM from three independent experiments (each performed in duplicate). ^{*d*}Determined by high-content imaging saturation binding at HEK293T-hH₂R-qs5 cells; mean values ± SEM from 2-3 experiments (each performed in duplicate). ^{*c*}Determined by GTPγS binding assay at membrane preparations of Sf9 insect cells expressing the hH₂R-G_{saS} fusion protein; pK_b values of neutral antagonists were determined in the antagonist mode versus histamine (c= 1 µM); mean values ± SEM from 2-3 independent experiments (each performed in triplicate). ^{*f*} Calculated from the K_i values obtained by conversion of the respective pK_i value (Table S2, Supporting Information). ^{*s*}Data was previously reported as K_i value by Baumeister *et al.*²⁸ and the raw data was re-analyzed to give the pK_i values. ^{*c*,*d*}Non-specific binding was determined in the presence of famotidine (300-fold excess). The incubation period was 60 min (*b*, *d*, *e*, *f*) or 90 min (*c*). n.d.: not determined. n.a.: not applicable.

The ligands **21**, comprising a positively charged pyridinium moiety, and **25**, comprising an electroneutral cyanine moiety, showed low non-specific binding at a concentration of 100 nM in the presence of famotidine (300-fold excess), whereas **23**, comprising a positively charged cyanine moiety, showed higher non-specific binding (Figure 2).

Fluorescent ligands **19-25**, which showed moderate to high hH_2R affinity ($pK_i > 6.0$) were used for flow cytometric binding studies at HEK293T-hH₂R-qs5 cells (Table 1; Figure S66-S68, Supporting Information). All investigated ligands afforded pK_d values which were in good agreement with the pK_i values. Within the pyridinium labeled ligands **19-21**, nonspecific binding was low (<10% of total binding around the K_d). The cyanine labeled ligands **22** and **23** with a positive charge of the fluorophore showed slightly higher non-specific binding (~20%). The introduction of a sulfonic acid group into the cyanine moiety resulting in an uncharged fluorophore (**24**,

), had a positive effect regarding non-specific binding (~10%).

The association and dissociation kinetics of **21**, **23** and **25** were determined on HEK293T-hH₂R-qs5 cells at 37 °C using flow cytometry (Figure S68, Table S3, Supporting Information). The fluorescent ligands showed a fast (k_{on} (**21**): 0.0043 min⁻¹ nM⁻¹) or moderate (k_{on} (**23**, **25**): 0.0009-0.002 min⁻¹ nM⁻¹) association rate and incomplete dissociation. A similar dissociation behavior was reported for the closely related radioligand [³H]UR-DE257.²⁸ A possible explanation for the (pseudo-)irreversible binding of these ligands is a slow dissociation from the receptor or binding to two different receptor states: a fast reversible and a tight-binding state (for more detailed information, see Supporting Information).²⁸ The estimated $pK_{d(kin)}$ values of **21**, **23** and **25**, were consistent with the pK_d values determined in saturation binding experiments, suggesting that binding followed at least in part the law of.

7

18 19

24

25

26

27

28 29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

60

21 (100 nM)

25 (100 nM)



Figure 2. Visualization of binding of the fluorescent ligands 21, 23 and 25 (all 100 nM) to the membrane of HEK293T-hH₂R-qs5 cells determined by confocal microscopy after 20 min of incubation at rt. Non-specific binding was determined in the presence of famotidine (300-fold excess). Images were acquired with a Zeiss Axiovert 200M microscope equipped with the LSM 510 Laser scanner. A 63x/1.40 oil immersion objective was used.

mass action. The (pseudo-)irreversibility of binding might be suboptimal for e.g. competition binding experiments, but might be advantageous in microscopy or even in in vivo (imaging) experiments The fluorescent ligands 19, 21-25 and 27 were also analyzed by automated cell imaging, enabling measurement of hH₂R binding on live and adherent HEK293T-hH2R-qs5 cells. Figure 3 shows representative images after incubation of the cells with the fluorescent ligands 21 (250 nM), 23 (75 nM), 25 (75 nM) and 27 (500 nM) at room temperature for 60 min, followed by a washing step. All fluorescent ligands were localized at the cell membrane. The pK_d values determined by saturation binding by automated cell imaging were generally in good agreement with those obtained by flow cytometry (Table 1; Figure S69-S70, Supporting Information).

The background fluorescence (binding to plastics) was low in case of fluorescent ligands with no or with negative charge of the fluorophore (24, 25, 27: <15% of total binding around the $K_{\rm d}$), but relatively high, if the ligand contained a fluorophore with positive charge (21: 25%; 22, 23: 30-40%). An exception was compound 19, which was also labeled with a positively charge Py-5, but showed a lower background fluorescence than 21 (~12%).

50 Investigation of the association and dissociation kinetics of the cyanine labeled ligand 25 with automated cell imaging re-51 vealed a much faster association (k_{on} : 0.0098 min⁻¹ nM⁻¹) com-52 pared to flow cytometry, but also an incomplete dissociation 53 (Figure S71-S72, Table S3, Supporting Information). The 54

residual fluorescent ligand was preferentially located at the cell membrane, and there was only very low fluorescence in the cytoplasm.

Results from saturation binding studies with 19 and 21 on suspended HEK293T-hH₂R-qs5 cells using an imaging flow cytometer were in good agreement with the results from automated cell imaging (Table 1; Figure S73-74, Supporting Information). The applicability of fluorescent ligands 21 and 25 for the determination of binding affinities of unlabeled ligands was demonstrated by flow cytometric and high content imaging competition binding assays (a more detailed description is provided in the Supporting information, Figure S75, Table S4).

For none of the investigated fluorescent ligands was a negative influence on cell viability during the incubation periods of the applied assays observed (flow cytometry and high content imaging (Figures S76-S78, Supporting Information).

Taken together, we showed that the presented fluorescent ligands are useful molecular tools for non-radioactive binding studies using different techniques such as confocal microscopy, (imaging) flow cytometry and automated cell imaging. The cyanine dye labeled ligands proved to be useful candidates for in vivo imaging as a high tissue permeability requires excitation and emission wavelengths in the far-red / nearinfrared $(>650 \text{ nm})^{35}$ and the pyridinium labeled ligands **19-21** might be suitable molecular tools (BRET acceptors) for Nano-BRET assays³⁰.



Figure 3. Visualization of binding of the fluorescent ligands **21** (250 nM), **23** (75 nM), **25** (75 nM) and **27** (500 nM) to the membrane of HEK293T-hH₂R-qs5 cells (red) determined by automated cell imaging after 60 min of incubation at rt. Hoechst 33342 was used as a nuclear stain (blue). Fluorescence was mainly associated with the plasma membrane. Non-specific binding was determined in the presence of famotidine (300-fold excess). Images were acquired with a IN Cell Analyzer 2000.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Synthesis of the intermediates **30-36**, BMY 25368 (**4**) and the amine precursors **16-18** (including Schemes S1 and S2); Experimental section (including Figures S1-S9); ¹H and ¹³C-NMR spectra of **30-36**, **4**, **16-27** (including Figures S10-S37); HPLC chromatograms of **16-27** and BMY 2536 (**4**) (including Figures S38-S40); HRMS spectra of compounds **30-36**, **4**, **16-27** (including Figures S41-S60), Determination of quantum yields (including Figure S61 and Table S1); Radioligand competition binding studies and GTP γ S binding assay (including Figures S62-S64 and Table S2); Investigation of β -arrestin2 recruitment by a split luciferase assay at HEK-hH₂R cells (including Figure S65); Binding studies of **19-25** at HEK293T-hH₂R-qs5 cells studied by flow cytometry (including Figures S66-S68 and Table S3); Binding of

19, **21-25** and **27** at HEK293T-hH₂R-qs5 cells studied by automated cell imaging (including Figures S69-S72); Saturation binding of **19** and **21** at HEK293T-hH₂R-qs5 cells studied by imaging flow cytometry (including Figures S73 and S74); Competition binding studies with **21** and **25** (including Figure S75 and Table S4); Rough estimate of cell viability (including Figures S76-S78).

Molecular formula strings (XLSX)

AUTHOR INFORMATION

Corresponding Author

*E-mail addresses: sabrina.biselli@ur.de (S.B.), guenther.bernhardt@ur.de (G.B.) Tel.: (+49)941 9432925 (S.B.), (+49)941 9434822 (G.B.) Fax: (+49)941 9434820 (S.B., G.B.)

Present Addresses

•Agrolab Labor GmbH, 84079 Bruckberg, Germany

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

*Zentrale Arzneimittelüberwachung Bayern, Germany

Sanofi Investment Co., Ltd., Chaoyang District, Beijing, China AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen am Rhein, Germany

Author Contributions

S.B., D.E., K.T. and M.C. performed the synthesis. S.B., I.A., T.L., A.F.M. and M.G-L. performed functional and binding studies. M.T. cloned the vector hH_2R -ELucC/ELucN- β -arrestin2 under supervision of T.O.. G.B. and A.B. initiated and planned the project. G.B., M.K., M.L. and A.B. supervised the research. S.B. and G.B. wrote the manuscript. All authors have given approval to the final version of the manuscript.

Funding

This work was funded by the Graduate Training Programs GRK760 (D.E., G.B. and A.B.) and GRK1910 (S.B., K.T., M.C., T.L., M.K. and A.B.) of the Deutsche Forschungsgemeinschaft (DFG) and the Elite Network of Bavaria (T.L. and A.B.).

Notes

The authors declare no competing financial interest. "Deceased, July 18, 2017.

ACKNOWLEDGMENT

The authors thank Paul Baumeister, Xueke She and Edith Bartole for helpful advices and Maria Beer-Krön, Elvira Schreiber, Dita Fritsch and Sieglinde Dechant for excellent technical assistance. We also thank Johannes Felixberger and Johannes Mosandl for preparation of the HEK293T-hH₂R-qs5 and HEK293T- β -Arr2hH₂R cells. The authors acknowledge the support of the project P2020-PTDC/BIM-MED/4041/2014 and of the i3S Scientific Platforms BioSciences Screening and Bioimaging, members of the PPBI (PPBI-POCI-01-0145-FEDER-022122).

ABBREVIATIONS

BSA, bovine serum albumin; BRET, bioluminescence energy transfer; cpm/cps, counts per minute/counts per second; DIPEA, diisopropylethylamine; GPCR, G-protein coupled receptor; GTPγS, guanosine 5'-thiotriphosphate; HEK293T, human embryonic kidney 293T; NBD, 4-nitrobenzo-2-oxa-1,3-diazole; PBS, phosphate buffered saline; pK_b , negative logarithm of the dissociation constant obtained from functional assays; pK_d , negative logarithm of the dissociation constant obtained from saturation binding experiments; pK_i , negative logarithm of the dissociation constant obtained from competition binding experiments; Sf9, Spodoptera frugiperda cells, TEA, triethylamine; TFA, trifluoroacetic acid.

REFERENCES

Black, J. W.; Duncan, W. A.; Durant, C. J.; Ganellin, C. R.; Parsons, E. M. Definition and antagonism of histamine H₂-receptors. *Nature* **1972**, 236, 385-390.

2. Domschke, W.; Domschke, S.; Classen, M.; Demling,
L. Histamine and cyclic 3',5'-AMP in gastric acid secretion. *Nature* 1973, 241, 454-455.

3. Reinhardt, D.; Schmidt, U.; Brodde, O. E.; Schumann, H. J. H_1 - and H_2 -receptor mediated responses to histamine on contractility and cyclic AMP of atrial and papillary muscles from guinea-pig hearts. *Agents Actions* **1977**, 7, 1-12.

4. Traiffort, E.; Pollard, H.; Moreau, J.; Ruat, M.; Schwartz, J. C.; Martinez-Mir, M. I.; Palacios, J. M. Pharmacological characterization and autoradiographic localization of histamine H_2 receptors in human brain identified

with [¹²⁵I]iodoaminopotentidine. J. Neurochem. **1992**, 59, 290-299.

5. Ruat, M.; Traiffort, E.; Bouthenet, M. L.; Schwartz, J. C.; Hirschfeld, J.; Buschauer, A.; Schunack, W. Reversible and Irreversible labeling and autoradiographic localization of the cerebral histamine H_2 -receptor using [I-125] iodinated probes. *P. Natl. Acad. Sci. USA* **1990**, 87, 1658-1662.

6. Reher, T. M.; Brunskole, I.; Neumann, D.; Seifert, R. Evidence for ligand-specific conformations of the histamine H₂-receptor in human eosinophils and neutrophils. *Biochem. Pharmacol.* **2012**, 84, 1174-1185.

7. Mitznegg, P.; Schubert, E.; Fuchs, W. Relations between the effects of histamine, pheniramin and metiamide on spontaneous motility and the formation of cyclic AMP in the isolated rat uterus. *Naunyn Schmiedeberg's Arch. Pharmacol.* **1975**, 287, 321-327.

8. Iliopoulos-Tsoutsouvas, C.; Kulkarni, R. N.; Makriyannis, A.; Nikas, S. P. Fluorescent probes for G-proteincoupled receptor drug discovery. *Expert Opin. Drug Discov.* **2018**, 13, 933-947.

9. Sridharan, R.; Zuber, J.; Connelly, S. M.; Mathew, E.; Dumont, M. E. Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. *Biochim. Biophys. Acta* **2014**, 1838, 15-33.

10. Rinken, A.; Lavogina, D.; Kopanchuk, S. Assays with detection of fluorescence anisotropy: Challenges and possibilities for characterizing ligand binding to GPCRs. *Trends Pharmacol. Sci.* **2018**, 39, 187-199.

11. Ciruela, F.; Jacobson, K. A.; Fernandez-Duenas, V. Portraying G protein-coupled receptors with fluorescent ligands. *ACS Chem. Biol.* **2014**, 9, 1918-1928.

12. Daval, S. B.; Valant, C.; Bonnet, D.; Kellenberger, E.; Hibert, M.; Galzi, J. L.; Ilien, B. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M₁ receptors. *J. Med. Chem.* **2012**, 55, 2125-2143.

13. Tahtaoui, C.; Parrot, I.; Klotz, P.; Guillier, F.; Galzi, J. L.; Hibert, M.; Ilien, B. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M_1 muscarinic receptor. *J. Med. Chem.* **2004**, 47, 4300-4315.

14. Jones, L. H.; Randall, A.; Napier, C.; Trevethick, M.; Sreckovic, S.; Watson, J. Design and synthesis of a fluorescent muscarinic antagonist. *Bioorg. Med. Chem. Lett.* **2008**, 18, 825-827.

15. Baker, J. G.; Adams, L. A.; Salchow, K.; Mistry, S. N.; Middleton, R. J.; Hill, S. J.; Kellam, B. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human beta-adrenoceptors. *J. Med. Chem.* **2011**, 54, 6874-6887.

16. Sugawara, T.; Hirasawa, A.; Hashimoto, K.; Tsujimoto, G. Differences in the subcellular localization of alphaladrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. *Life. Sci.* **2002**, 70, 2113-2124.

17. Li, L.; Kracht, J.; Peng, S.; Bernhardt, G.; Buschauer, A. Synthesis and pharmacological activity of fluorescent histamine H_1 receptor antagonists related to mepyramine. *Bioorg. Med. Chem.* **2003**, 13, 1245-1248.

18. Rose, R. H.; Briddon, S. J.; Hill, S. J. A novel fluorescent histamine H_1 receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands. *Br. J. Pharmacol.* **2012**, 165, 1789-1800.

19. Isensee, K.; Amon, M.; Garlapati, A.; Ligneau, X.; Camelin, J. C.; Capet, M.; Schwartz, J. C.; Stark, H. Fluorinated non-imidazole histamine H_3 receptor antagonists. *Bioorg. Med. Chem. Lett.* **2009**, 19, 2172-2175.

20. Amon, M.; Ligneau, X.; Schwartz, J. C.; Stark, H. Fluorescent non-imidazole histamine H_3 receptor ligands with

nanomolar affinities. Bioorg. Med. Chem. Lett. 2006, 16, 1938-1940.

1

2

3

4

5

6

7

8

9

11

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29 30 31

32 33

34

35

44

45

60

Amon, M.; Ligneau, X.; Camelin, J. C.; Berrebi-21. Bertrand, I.; Schwartz, J. C.; Stark, H. Highly potent fluorescence-tagged nonimidazole histamine H₃ receptor ligands. ChemMedChem 2007, 2, 708-716.

Sabnis, R. W. Handbook of Fluorescent Dyes and 22. Probes. John Wiley & Sons, Inc: Hoboken, 2015.

23. Li, L.; Kracht, J.; Peng, S.; Bernhardt, G.; Elz, S.; Buschauer, A. Synthesis and pharmacological activity of fluorescent histamine H₂ receptor antagonists related to potentidine. Bioorg. Med. Chem. Lett. 2003, 13, 1717-1720. 10

Malan, S. F.; van Marle, A.; Menge, W. M.; Zuliani, V.; 24. Hoffman, M.; Timmerman, H.; Leurs, R. Fluorescent ligands for 12 the histamine H₂ receptor: synthesis and preliminary 13 characterization. Bioorg. Med. Chem. 2004, 12, 6495-6503. 14

Xie, S. X.; Petrache, G.; Schneider, E.; Ye, Q. Z.; 25 Bernhardt, G.; Seifert, R.; Buschauer, A. Synthesis and pharmacological characterization of novel fluorescent histamine H₂-receptor ligands derived from aminopotentidine. Bioorg. Med. Chem. Lett. 2006, 16, 3886-3890.

26. Petrache, G.; Pavelescu, M. D. The pharmacological activity of some new fluorescent small molecule histamine H₂ receptor (H2R) ligands, derived from aminopotentidine and squaramide, in the GTPase assay. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010, 114, 255-259.

27. Hill, S. J.; Kellam, B.; Briddon, S. J. Fluorescencebased high content screening of compounds for functional response or pharmacological properties. 2006032926, 2006. Chem. Abstr. 144:343538.

Baumeister, P.; Erdmann, D.; Biselli, S.; Kagermeier, 28. N.: Elz. S.: Bernhardt, G.: Buschauer, A. [³H]UR-DE257: Development of a tritium-labeled squaramide-type selective

histamine H₂ receptor antagonist. ChemMedChem 2015, 10, 83-93

29. R. R. Algieri, A. A.; Crenshaw, 1.2-Diaminocyclobutene-3,4-diones pharmaceutical and а composition containing them. FR 2505835, 1982. Chem. Abstr. 99:22320.

Keller, M.; Mahuroof, S.; Hong Yee, V.; Carpenter, J.; 30 Schindler, L.; Littmann, T.; Pegoli, A.; Hübner, H.; Bernhardt, G.; Gmeiner, P.; Holliday, N. D. Fluorescence labeling of neurotensin(8-13) via arginine residues gives molecular tools with high receptor affinity. ACS Med. Chem. Lett. published November 2019, online DOI: 10.1021/acsmedchemlett.1029b00462.

Brown, T. H.; Young, R. C. Dioxocyclobutene 31. compounds. EP 105702, 1986. Chem. Abstr. 101:130290

32. Wetzl, B. K.; Yarmoluk, S. M.; Craig, D. B.; Wolfbeis, O. S. Chameleon labels for staining and quantifying proteins. Angew. Chem. Int. Ed. Eng.l 2004, 43, 5400-5402.

Dunn, S. M. J.; Fluorescence measurements of receptor-33. ligand interactions. In handbook of neurochemistry and molucular neurobiology, 3rd ed.;Lajtha, A; Baker, G.; Dunn, S.; Holt, A., Eds.; Springer Science + Buisness Media, LLC.: New York, 2007; 133-148.

Kelley, M. T.; Bürckstümmer, T.; Wenzel-Seifert, K.; 34. Dove, S.; Buschauer, A.; Seifert, R. Distinct interaction of human and guinea pig histamine H₂-receptor with guanidine-type agonists. Mol. Pharmacol. 2001, 60, 1210-1225.

Chen, C.; Hua, Y.; Hu, Y.; Fang, Y.; Ji, S.; Yang, Z.; 35. Ou, C.; Kong, D.; Ding, D. Far-red/near-infrared fluorescence light-up probes for specific in vitro and in vivo imaging of a tumour-related protein. Sci. Rep. 2016, 6, 23190.

Dale, N. C.: Johnstone, E. K. M.: White, C. W.: Pfleger, 36. K. D. G. NanoBRET: The bright future of proximity-based assays. Front. Bioeng. Biotechnol. 2019, 7, 56.

For Table of Contents Use Only

Title: Fluorescent H₂ Receptor Squaramide-Type Antagonists: Synthesis, Characterization and Applications Authors: Sabrina Biselli, Inês Alencastre, Katharina Tropmann, Daniela Erdmann, Mengya Chen, Timo Littmann, André F. Maia, Maria Gomez-Lazaro, Miho Tanaka, Takeaki Ozawa, Max Keller, Meriem Lamghari, Armin Buschauer and Günther Bernhardt

